Ysios Capital strengthens its team with internal promotions and a new Venture Partner

BARCELONA, Spain - Rezul -- Ysios Capital, a European life sciences venture capital firm, today announced the promotions of Jordi Xiol to Partner and Salvatore Scaffidi to Associate, as well as the appointment of Joan Perelló as Venture Partner.
Jordi Xiol joined Ysios Capital in 2019 as an Associate and his contribution to the identification and evaluation of investment opportunities has been outstanding. Prior to joining Ysios, Jordi worked at Vida Ventures in Boston, where he focused on opportunities in oncology, gene therapy, and ophthalmology. In his new role he will be responsible for making and managing investments. He is currently a member of the board of directors of Northsea Therapeutics and Splice Bio, and an observer on the board of directors of Adcendo and Cytoki.

More on Rezul News

• Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
• Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
• Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
• Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
• Over 98% of crypto owners globally don't declare taxes, new report find

Salvatore Scaffidi joined Ysios Capital in 2021 as an Analyst after successfully completing Ysios' Fellowship program. Prior to joining Ysios, Salvatore received a PhD from the University of Barcelona (UB), where he studied protein-ligand complexes using biophysical techniques. As an Associate, he will source and evaluate investment opportunities. Salvatore is currently a board observer at Splice Bio.
"The human capital is our key and only asset. These promotions reflect our commitment to foster and value top talent." commented Joël Jean-Mairet, Managing Partner at Ysios Capital.
Joan Perelló, a highly accomplished serial life sciences entrepreneur, has been appointed as a new Venture Partner at Ysios Capital.  With 15+ years of management experience in various organizations, including as CEO, Non-Executive Director, President and Chairman, Joan Perelló is a respected figure in the life sciences industry. He is co-founder and CEO of Sanifit, a biotech company that raised over €140M in equity and debt financing before it was acquired by Vifor for €375M + sales milestones, the biggest exit of the Spanish Biotech sector. Joan is Chairman of the Board at CIRCE Crystal Engineering, President of the Balearic Cluster of Biotechnology and Biomedicine and Vice-Dean at the Official College of Chemists in the Balearic Islands, Spain.

More on Rezul News

• A Simple Price Adjustment Turned Into Multiple Offers in Troy, NY
• TicTac Group acquires French EdTech company Distrisoft
• Central Florida Realtor Guides Out-of-State Buyers Through Florida's Diverse Housing Markets
• New Residential & Acreage, Recreational Land And Income Properties With Iowa Realtor Randy Willie
• Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet

Joan Perelló holds an MSc in Chemistry with first-class honors and earned his PhD from the University of the Balearic Islands, Spain, where he teaches Analytical and Clinical Chemistry as an Associate Professor.
"I have known the Ysios team for over a decade and have long admired their work in building Europe's, and in particular Spain's, leading life sciences companies. With their strong brand, international network, and excellent scientific backgrounds, they transform capital into medical breakthroughs." commented Joan Perelló, Venture Partner at Ysios Capital.
Julia Salaverria, Managing Partner at Ysios also added: "Joan is a highly accomplished serial entrepreneur and has created one of the key success stories in Spain. We are honored to be working with him as we continue to build leading life sciences companies."
Joan Perelló will join Ysios Capital Venture Partners' base of internationally renowned experts currently formed by Toni Ribas, world expert in immuno-oncology, former President of the American Association for Cancer Research (AACR) and Professor at the University of California Los Angeles (UCLA); Pamela Klein, former VP Development at Genentech/Roche; Carlos Payá, expert in Immunology and infectious diseases, previously in various leadership roles at Eli Lilly in and CEO of Immune Design until its acquisition by Merck & Co., David Lacey, former Senior VP and Global Head of Discovery Research at Amgen, and Lance Berman who has more than 20 years of clinical development experience in big pharma and the biotech start-ups.